These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
743 related articles for article (PubMed ID: 33973876)
21. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study. van Wyk J; Ajana F; Bisshop F; De Wit S; Osiyemi O; Portilla Sogorb J; Routy JP; Wyen C; Ait-Khaled M; Nascimento MC; Pappa KA; Wang R; Wright J; Tenorio AR; Wynne B; Aboud M; Gartland MJ; Smith KY Clin Infect Dis; 2020 Nov; 71(8):1920-1929. PubMed ID: 31905383 [TBL] [Abstract][Full Text] [Related]
22. 72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study. Malaba TR; Nakatudde I; Kintu K; Colbers A; Chen T; Reynolds H; Read L; Read J; Stemmet LA; Mrubata M; Byrne K; Seden K; Twimukye A; Theunissen H; Hodel EM; Chiong J; Hu NC; Burger D; Wang D; Byamugisha J; Alhassan Y; Bokako S; Waitt C; Taegtmeyer M; Orrell C; Lamorde M; Myer L; Khoo S; Lancet HIV; 2022 Aug; 9(8):e534-e543. PubMed ID: 35905752 [TBL] [Abstract][Full Text] [Related]
23. Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV. Paton NI; Musaazi J; Kityo C; Walimbwa S; Hoppe A; Balyegisawa A; Kaimal A; Mirembe G; Tukamushabe P; Ategeka G; Hakim J; Mugerwa H; Siika A; Asienzo J; Castelnuovo B; Kiragga A; Kambugu A; N Engl J Med; 2021 Jul; 385(4):330-341. PubMed ID: 34289276 [TBL] [Abstract][Full Text] [Related]
24. Dolutegravir-based dual maintenance regimens combined with lamivudine/emtricitabine or rilpivirine: risk of virological failure in a real-life setting. Deschanvres C; Reynes J; Lamaury I; Rey D; Palich R; Bani-Sadr F; Robineau O; Duvivier C; Hocqueloux L; Cuzin L; Joly V; Raffi F; Cabie A; Allavena C; J Antimicrob Chemother; 2021 Dec; 77(1):196-204. PubMed ID: 34651192 [TBL] [Abstract][Full Text] [Related]
25. Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance. Acosta RK; Willkom M; Andreatta K; Liu H; Martin R; Parvangada A; Martin H; Collins S; White KL J Acquir Immune Defic Syndr; 2020 Nov; 85(3):363-371. PubMed ID: 32701823 [TBL] [Abstract][Full Text] [Related]
26. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Cahn P; Madero JS; Arribas JR; Antinori A; Ortiz R; Clarke AE; Hung CC; Rockstroh JK; Girard PM; Sievers J; Man C; Currie A; Underwood M; Tenorio AR; Pappa K; Wynne B; Fettiplace A; Gartland M; Aboud M; Smith K; Lancet; 2019 Jan; 393(10167):143-155. PubMed ID: 30420123 [TBL] [Abstract][Full Text] [Related]
28. Efficacy and Tolerability of Tenofovir/Lamivudine/Dolutegravir among Antiretroviral Therapy Naive Human Immunodeficiency Virus Infected Patients of a Tertiary Care Center in Eastern India. Sengupta D; Ghosh S; Pain S; Chatterjee N J Assoc Physicians India; 2023 Sep; 71(9):72-74. PubMed ID: 38700305 [TBL] [Abstract][Full Text] [Related]
29. M184V/I does not impact the efficacy of abacavir/lamivudine/dolutegravir use as switch therapy in virologically suppressed patients. Jary A; Marcelin AG; Charpentier C; Wirden M; Lê MP; Peytavin G; Descamps D; Calvez V J Antimicrob Chemother; 2020 May; 75(5):1290-1293. PubMed ID: 32065630 [TBL] [Abstract][Full Text] [Related]
30. ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mL. Taiwo BO; Zheng L; Stefanescu A; Nyaku A; Bezins B; Wallis CL; Godfrey C; Sax PE; Acosta E; Haas D; Smith KY; Sha B; Van Dam C; Gulick RM Clin Infect Dis; 2018 May; 66(11):1689-1697. PubMed ID: 29253097 [TBL] [Abstract][Full Text] [Related]
31. Initial Supplementary Dose of Dolutegravir in Second-Line Antiretroviral Therapy: A Noncomparative, Double-Blind, Randomized Placebo-Controlled Trial. Zhao Y; Griesel R; Omar Z; Simmons B; Hill A; van Zyl G; Keene C; Maartens G; Meintjes G Clin Infect Dis; 2023 May; 76(10):1832-1840. PubMed ID: 36645792 [TBL] [Abstract][Full Text] [Related]
32. Low-level viraemia and virologic failure among people living with HIV who received maintenance therapy with co-formulated bictegravir, emtricitabine and tenofovir alafenamide versus dolutegravir-based regimens. Chen GJ; Sun HY; Chen LY; Hsieh SM; Sheng WH; Liu WD; Chuang YC; Huang YS; Lin KY; Wu PY; Chang HY; Luo YZ; Su YC; Liu WC; Chang SF; Chang SY; Hung CC Int J Antimicrob Agents; 2022 Sep; 60(3):106631. PubMed ID: 35787920 [TBL] [Abstract][Full Text] [Related]
33. Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1. ; Kouanfack C; Mpoudi-Etame M; Omgba Bassega P; Eymard-Duvernay S; Leroy S; Boyer S; Peeters M; Calmy A; Delaporte E N Engl J Med; 2019 Aug; 381(9):816-826. PubMed ID: 31339676 [TBL] [Abstract][Full Text] [Related]
34. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Sax PE; Pozniak A; Montes ML; Koenig E; DeJesus E; Stellbrink HJ; Antinori A; Workowski K; Slim J; Reynes J; Garner W; Custodio J; White K; SenGupta D; Cheng A; Quirk E Lancet; 2017 Nov; 390(10107):2073-2082. PubMed ID: 28867499 [TBL] [Abstract][Full Text] [Related]
35. Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection. Deng L; Li C; Chen P; Luo X; Zheng X; Zhou L; Zhou Y; Xia J; Hong Z BMC Infect Dis; 2022 Jan; 22(1):17. PubMed ID: 34983415 [TBL] [Abstract][Full Text] [Related]
36. Assessment of weight gain in adult patients living with HIV receiving first-line dolutegravir-based or efavirenz-based ART regimens in routine care clinics in Tshwane district, South Africa: An observational study. Sawry S; Ayalew K; Maimela G; Briggs-Hagen M; van Wyk-Heath M; Mthethwa S; Shai S; Mngomezulu NN; Tlhowe L; Achere-Darko J; Bedford J; Martin CE; Fairlie L; Imrie J HIV Med; 2024 Jul; 25(7):826-839. PubMed ID: 38520085 [TBL] [Abstract][Full Text] [Related]
37. Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study. Orrell C; Hagins DP; Belonosova E; Porteiro N; Walmsley S; Falcó V; Man CY; Aylott A; Buchanan AM; Wynne B; Vavro C; Aboud M; Smith KY; Lancet HIV; 2017 Dec; 4(12):e536-e546. PubMed ID: 28729158 [TBL] [Abstract][Full Text] [Related]
38. HIV-1 pretreatment and acquired antiretroviral drug resistance before tenofovir/ /lamivudine /dolutegravir (TLD) roll-out in Mozambique. Ismael N; Gemusse H; Mahumane I; Laurindo O; Magul C; Baxter C; Wilkinson E; Hofstra LM; Wagar N; Bila D; Mabunda N; da Silva J; Oliveira T; Raizes E; Preiser W; Manuel P; Ramos A; Vúbil A BMC Infect Dis; 2024 Jul; 24(1):748. PubMed ID: 39075381 [TBL] [Abstract][Full Text] [Related]
39. Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon. Calmy A; Tovar Sanchez T; Kouanfack C; Mpoudi-Etame M; Leroy S; Perrineau S; Lantche Wandji M; Tetsa Tata D; Omgba Bassega P; Abong Bwenda T; Varloteaux M; Tongo M; Mpoudi-Ngolé E; Montoyo A; Mercier N; LeMoing V; Peeters M; Reynes J; Delaporte E; Lancet HIV; 2020 Oct; 7(10):e677-e687. PubMed ID: 33010241 [TBL] [Abstract][Full Text] [Related]
40. A Phase-IV Non-interventional Study to Assess Virological Effectiveness, Safety, and Tolerability of DTG-based Antiretroviral Therapy in HIV-1 Infected Indian Persons Living with HIV. Ashta KK; Arora S; Khanna R; Raman N; Anilkumar A; Mohan C Curr HIV Res; 2024; 22(1):31-46. PubMed ID: 38284697 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]